Study 7 of 19Degarelix literaturebiorxiv-preprint · RCT2026

Effects of a Modified Injection Technique on Pain and Injection-Site Reactions to Degarelix Acetate in Patients with Advanced Prostate Cancer

The modified injection technique for degarelix acetate resulted in significantly lower pain scores and milder injection-site reactions, potentially improving the patient experience.

Read at biorxiv-preprint Add to compare

Where it sits

this study against the rest of the degarelix corpus

Preclinical

Observational

Open-label

Randomised · this one

Reviews

Summary and findings

This study evaluated the effects of a modified injection protocol on pain and injection-site reactions in 180 patients with advanced prostate cancer receiving 240 mg degarelix acetate. The modified protocol involved abdominal muscle relaxation and a 1-minute slow phased injection compared to a standard rapid injection. The experimental group reported significantly lower pain scores and milder injection-site reactions.

How much of this paper we could read: full text read (0.90). We had a clear abstract, so the summary below closely tracks the paper. What this means →

VAS pain score at 72 h: 0.9±0.5 in modified group vs 2.3±1.0 in standard group, p<0.001.2026

Abstract

The authors’ words, as biorxiv-preprint supplied them

<title>Abstract</title> <p> <bold>Background:</bold> To evaluate whether a modified injection protocol reduces pain and injection-site reactions (ISRs) to 240 mg degarelix acetate in advanced prostate cancer patients. <bold>Methods:</bold> A <bold/> single-center, prospective, randomized controlled trial was conducted. 180 patients were randomized at 1:1 to modified protocol (abdominal muscle relaxation and 1-minute slow phased injection) or standard rapid injection. Primary outcome: VAS pain score at 72 h; secondary outcomes: ISRs and patient experience. Data was collected between January 2024 and August 2025. <bold>Results:</bold> The experimental group had significantly lower 72 h VAS pain (0.9±0.5 vs 2.3±1.0, p<0.001) and milder swelling, erythema, induration, pruritus (all p<0.001). Patient satisfaction and re-treatment willingness were higher; no serious adverse events. <bold>Conclusion:</bold> The modified protocol effectively reduces pain, drug aggregation and ISRs, with good reproducibility and clinical practicality. It improves treatment experience, adherence, and provides a reference for optimizing injection of high-viscosity subcutaneous drugs. <bold>Trial registration:</bold> This trial was registered at the Chinese Clinical Trial Registry (ChiCTR2400087654) on January 1, 2024. The trial protocol was consistent with the registered version. </p>

Elsewhere in the Degarelix corpus

AEffect of neoadjuvant androgen deprivation therapy on prostate and tumor morphology prior to MRI-guided transurethral ultrasound ablation of prostate cancer.International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group · 2026 · n=15 · PSA declined by 87% (-7.6 ng/mL; 95% CI. -9.7 to -5.7; p < 0.001)Human BFewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan.Cancer reports (Hoboken, N.J.) · 2026 · n=2276025 · Injections decreased by 21.5%, from 1,275,081 to 1,000,324.Human BFewer Injections and Lower Drug Costs With Long-Acting GnRH Depot Formulations: A Nationwide Analysis of 2.3 Million Patient-Years in Japan.Cancer reports (Hoboken, N.J.) · 2023 · n=2276025 · Injections decreased by 21.5%, from 1,275,081 to 1,000,324.Human BBone-related adverse events of hormonal therapy: A pharmacovigilance study based on the Food & Drug Administration Adverse Event Reporting System.The Journal of international medical research · 2026 · Not reported in abstract.review BPeribronchial cuffing: an underrecognized pattern of prostate carcinoma metastases to the lung.BJC reports · 2023 · n=9 · 55% of patients died within a median of 5.3 months from radiographic detection.Human BPulmonary tumor thrombotic microangiopathy associated with prostate cancer achieving over 10-year survival: a case report.International cancer conference journal · 2026 · n=1 · Not reported in abstract.Human